Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo

S. Kase, T. Kubota, M. Watanabe, Toshiharu Furukawa, H. Tanino, K. Ishibiki, T. Teramoto, M. Kitajima

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The modulating effect of human fibroblast-derived interferon beta (IFN-β) on the antitumor effect of 5-fluorouracil (5-FU) against human colon carcinoma cells in vitro and in vivo was investigated. The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H tetrazolium bromide (MTT) assay was carried out in vitro using the cultured human colon cancer cell line C-1. IFN-β at concentrations of 50, 500, 5,000 and 50,000 IU/ml was added to the cultured tumor cells with or without 5-FU at concentrations of 10, 50 and 500 ug/ml. The antitumor activity of 5-FU with or without IFN-β. was assessed using Co-4, a human colon carcinoma xenograft in nude mice, with reference to thymidylate synthetase inhibition. IFN-β was administered subcutaneously daily for 14 days at doses of 6,000, 60,000 and 600,000 IU/mouse. The combined antitumor effect. with 5-FU was evaluated by simultaneous intraperitoneal administration of 5-FU at doses of 10 and 20 mg/kg daily for 10 days. The antitumor activity of IFN-β alone increased in a dose-dependent manner against Co-4 in nude mice whereas its antitumor activity in vitro against C-1 was limited. The synergistic effect of 5-FU and IFN-β was observed both in vitro and in vivo, and the in vivo synergism was obtained without any enhancement of thymidylate synthetase inhibition or side effects in terms of death rate and body weight loss. These results suggest that the mechanism of the combined effect of 5-FU and IFN-β is not related to enhancement of thymidylate synthetase inhibition or the host immune system, since human fibroblastoid IFN-β is species-specific to humans. The clinical usefulness of this combination method for the treatment of advanced colorectal carcinoma is expected.

Original languageEnglish
Pages (from-to)369-373
Number of pages5
JournalAnticancer Research
Volume13
Issue number2
Publication statusPublished - 1993

Fingerprint

Interferon-beta
Fluorouracil
Colon
Carcinoma
Thymidylate Synthase
Nude Mice
Cultured Tumor Cells
In Vitro Techniques
Heterografts
Colonic Neoplasms
Weight Loss
Colorectal Neoplasms
Immune System
Body Weight
Cell Line
Mortality

Keywords

  • 5-fluorouracil
  • Human colon carcinoma
  • Interferon beta

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kase, S., Kubota, T., Watanabe, M., Furukawa, T., Tanino, H., Ishibiki, K., ... Kitajima, M. (1993). Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo. Anticancer Research, 13(2), 369-373.

Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo. / Kase, S.; Kubota, T.; Watanabe, M.; Furukawa, Toshiharu; Tanino, H.; Ishibiki, K.; Teramoto, T.; Kitajima, M.

In: Anticancer Research, Vol. 13, No. 2, 1993, p. 369-373.

Research output: Contribution to journalArticle

Kase, S, Kubota, T, Watanabe, M, Furukawa, T, Tanino, H, Ishibiki, K, Teramoto, T & Kitajima, M 1993, 'Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo', Anticancer Research, vol. 13, no. 2, pp. 369-373.
Kase, S. ; Kubota, T. ; Watanabe, M. ; Furukawa, Toshiharu ; Tanino, H. ; Ishibiki, K. ; Teramoto, T. ; Kitajima, M. / Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo. In: Anticancer Research. 1993 ; Vol. 13, No. 2. pp. 369-373.
@article{5efaa6d5180948a6ba5ea57e0785cec9,
title = "Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo",
abstract = "The modulating effect of human fibroblast-derived interferon beta (IFN-β) on the antitumor effect of 5-fluorouracil (5-FU) against human colon carcinoma cells in vitro and in vivo was investigated. The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H tetrazolium bromide (MTT) assay was carried out in vitro using the cultured human colon cancer cell line C-1. IFN-β at concentrations of 50, 500, 5,000 and 50,000 IU/ml was added to the cultured tumor cells with or without 5-FU at concentrations of 10, 50 and 500 ug/ml. The antitumor activity of 5-FU with or without IFN-β. was assessed using Co-4, a human colon carcinoma xenograft in nude mice, with reference to thymidylate synthetase inhibition. IFN-β was administered subcutaneously daily for 14 days at doses of 6,000, 60,000 and 600,000 IU/mouse. The combined antitumor effect. with 5-FU was evaluated by simultaneous intraperitoneal administration of 5-FU at doses of 10 and 20 mg/kg daily for 10 days. The antitumor activity of IFN-β alone increased in a dose-dependent manner against Co-4 in nude mice whereas its antitumor activity in vitro against C-1 was limited. The synergistic effect of 5-FU and IFN-β was observed both in vitro and in vivo, and the in vivo synergism was obtained without any enhancement of thymidylate synthetase inhibition or side effects in terms of death rate and body weight loss. These results suggest that the mechanism of the combined effect of 5-FU and IFN-β is not related to enhancement of thymidylate synthetase inhibition or the host immune system, since human fibroblastoid IFN-β is species-specific to humans. The clinical usefulness of this combination method for the treatment of advanced colorectal carcinoma is expected.",
keywords = "5-fluorouracil, Human colon carcinoma, Interferon beta",
author = "S. Kase and T. Kubota and M. Watanabe and Toshiharu Furukawa and H. Tanino and K. Ishibiki and T. Teramoto and M. Kitajima",
year = "1993",
language = "English",
volume = "13",
pages = "369--373",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo

AU - Kase, S.

AU - Kubota, T.

AU - Watanabe, M.

AU - Furukawa, Toshiharu

AU - Tanino, H.

AU - Ishibiki, K.

AU - Teramoto, T.

AU - Kitajima, M.

PY - 1993

Y1 - 1993

N2 - The modulating effect of human fibroblast-derived interferon beta (IFN-β) on the antitumor effect of 5-fluorouracil (5-FU) against human colon carcinoma cells in vitro and in vivo was investigated. The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H tetrazolium bromide (MTT) assay was carried out in vitro using the cultured human colon cancer cell line C-1. IFN-β at concentrations of 50, 500, 5,000 and 50,000 IU/ml was added to the cultured tumor cells with or without 5-FU at concentrations of 10, 50 and 500 ug/ml. The antitumor activity of 5-FU with or without IFN-β. was assessed using Co-4, a human colon carcinoma xenograft in nude mice, with reference to thymidylate synthetase inhibition. IFN-β was administered subcutaneously daily for 14 days at doses of 6,000, 60,000 and 600,000 IU/mouse. The combined antitumor effect. with 5-FU was evaluated by simultaneous intraperitoneal administration of 5-FU at doses of 10 and 20 mg/kg daily for 10 days. The antitumor activity of IFN-β alone increased in a dose-dependent manner against Co-4 in nude mice whereas its antitumor activity in vitro against C-1 was limited. The synergistic effect of 5-FU and IFN-β was observed both in vitro and in vivo, and the in vivo synergism was obtained without any enhancement of thymidylate synthetase inhibition or side effects in terms of death rate and body weight loss. These results suggest that the mechanism of the combined effect of 5-FU and IFN-β is not related to enhancement of thymidylate synthetase inhibition or the host immune system, since human fibroblastoid IFN-β is species-specific to humans. The clinical usefulness of this combination method for the treatment of advanced colorectal carcinoma is expected.

AB - The modulating effect of human fibroblast-derived interferon beta (IFN-β) on the antitumor effect of 5-fluorouracil (5-FU) against human colon carcinoma cells in vitro and in vivo was investigated. The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H tetrazolium bromide (MTT) assay was carried out in vitro using the cultured human colon cancer cell line C-1. IFN-β at concentrations of 50, 500, 5,000 and 50,000 IU/ml was added to the cultured tumor cells with or without 5-FU at concentrations of 10, 50 and 500 ug/ml. The antitumor activity of 5-FU with or without IFN-β. was assessed using Co-4, a human colon carcinoma xenograft in nude mice, with reference to thymidylate synthetase inhibition. IFN-β was administered subcutaneously daily for 14 days at doses of 6,000, 60,000 and 600,000 IU/mouse. The combined antitumor effect. with 5-FU was evaluated by simultaneous intraperitoneal administration of 5-FU at doses of 10 and 20 mg/kg daily for 10 days. The antitumor activity of IFN-β alone increased in a dose-dependent manner against Co-4 in nude mice whereas its antitumor activity in vitro against C-1 was limited. The synergistic effect of 5-FU and IFN-β was observed both in vitro and in vivo, and the in vivo synergism was obtained without any enhancement of thymidylate synthetase inhibition or side effects in terms of death rate and body weight loss. These results suggest that the mechanism of the combined effect of 5-FU and IFN-β is not related to enhancement of thymidylate synthetase inhibition or the host immune system, since human fibroblastoid IFN-β is species-specific to humans. The clinical usefulness of this combination method for the treatment of advanced colorectal carcinoma is expected.

KW - 5-fluorouracil

KW - Human colon carcinoma

KW - Interferon beta

UR - http://www.scopus.com/inward/record.url?scp=0027155348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027155348&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 369

EP - 373

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -